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other treatment related effects such as nausea. The present study
was designed to estimate the utility decrement associated with
increasing severities of anaemia. METHODS: Existing trial data
was summarized in order to deﬁne health states related to the
following haemoglobin levels: 7.0–8.0; 8.0–9.0; 9.0–10.0;
10.0–10.5; 10.5–11.0; 11.0–12.0; and 12+g/dL. These health
states were based on the FACT-An fatigue related items and were
reviewed by clinicians and two quality of life experts. Forty inter-
views with the general public (recruited through advertisements)
were conducted where participants were asked to rate the health
states using a visual analogue scale (VAS) and standard gamble
(SG). RESULTS: Mean (+95% CI) utility values were calculated
for each health state anchored against death. The VAS scores
ranged from 19.3 ± 3.9 for 7–8g/dL Hb to 53.8 3 ± 6.7 for 12+
g/dL Hb. The standard gamble derived utility values showed a
broadly linear change from 0.59 ± 0.10 for 7–8g/dL Hb to 0.75
± 0.09 for 12+g/dL Hb. CONCLUSIONS: The health state
utility scores show a linear decrement in line with worsening
anaemia. These data underline the importance of cancer related
fatigue for the general public.
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OBJECTIVES: Anaemia is a common complication in cancer
patients undergoing chemotherapy. Although quality-of-life
(QoL) in CRA has been studied, utility values related to anaemia
severity are lacking. The UK National Institute for Clinical
Excellence (NICE) requests cost-utility analysis based on quality-
adjusted life-years (QALY’s) incorporating utilities elicited using
public preferences. The objective was to use an appropriate
method to estimate the impact of CRA, from a societal perspec-
tive. METHODS: A time-trade-off (TTO) questionnaire was
designed and administered to a sample of laypeople: CRA health
states were deﬁned and described, based on the EuroQoL (EQ-
5D) instrument, and the Functional Assessment of Cancer
Therapy—Anaemia (FACT-An) instrument, and validated by
clinical experts and cancer patients who had experienced
anaemia. These descriptions were valued using the TTO elicita-
tion method. Written informed consent was obtained and trained
interviewers conducted surveys during February–March, 2004.
RESULTS: In total, 110 respondents were interviewed; ﬁnal
analyses were performed on 106 respondents’ data. Resultant
utility scores were converted to ratios, reﬂecting the baseline of
“cancer and chemotherapy, with no anaemia”. Mean utility
scores [SE] are 0.856 [0.014] for the no-anaemia state, and 0.781
[0.016], 0.615 [0.020] and 0.481 [0.020] for mild, moderate and
severe anaemia states, respectively (Ratios of 1.00, 0.91, 0.72,
and 0.56, respectively). CONCLUSIONS: This study strongly
highlights a societal view that severity of cancer-related anaemia
will signiﬁcantly affect patient utility. For example, a change
from no-anaemia to severe anaemia is predicted to approxi-
mately halve utility, independent of other factors. TTO 
appears to be a valid, and sufﬁciently sensitive method to high-
light this effect. The ratios of relative effect are applicable to a
range of “baseline” cancer utilities as multiplicative factors 
to estimate impact of anaemia within this broader context. 
These results could be incorporated within appraisals of thera-
pies for CRA, and satisfy certain health technology assessment
criteria.
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OBJECTIVES: Blood transfusion and rh-EPO are alternative
treatment options for CRA. Potential beneﬁts of rh-EPO treat-
ment include improved health outcomes, but also more conve-
nient administration. The objective was to elicit public
preference scores associated with differences in these aspects of
treatment, and subsequently use these “valued preferences”
within a willingness-to-pay (WTP) analysis of cost-effectiveness
of NeoRecormon (rh-EPO beta) versus transfusion. METHODS:
A discrete choice experiment (DCE) was designed and adminis-
tered to a sample of laypeople. Important aspects of treatment
were deﬁned through a literature review, plus input from expert
clinician and patient interviews. An out-of-pocket cost attribute
was included in order to estimate WTP values. Lay people were
surveyed during February–March, 2004. A random effects probit
model was used to analyse the data. WTP values for aspects of
treatment were obtained by estimating the marginal rate of sub-
stitution between treatment attributes and the cost coefﬁcient.
Mean values of a unit improvement in each attribute level were
used in an economic welfare analysis of the value of shifting from
transfusion to NeoRecormon. RESULTS: A total of 110 respon-
dents completed the DCE questionnaire. Final analyses were per-
formed on 1086 observations, and showed high consistency,
reliability, and face-validity. The following preferences were sig-
niﬁcant predictors of choice (p < 0.001): Effectiveness: Higher
level of relief from fatigue; Administration of treatment: Lower
duration, subcutaneous/intravenous versus cannula injection,
and GP versus hospital location; Safety: Lower risk of infec-
tion/allergic reaction; and Lower cost. Attribute levels were
valued higher for NeoRecormon than for transfusion. This is
reﬂected in an incremental welfare value of GBP368[95% CI:
GBP318-GBP419]. CONCLUSIONS: This study shows that the
public value the favourable attributes of treatment with rh-EPO,
and indicates a likely patient preference for treatment with Neo-
Recormon over blood transfusion. This type of WTP analysis
could be used to aid decisions regarding optimal management of
CRA.
CANCER
CANCER—Health Policy
PCN36
THE VALUE OF THE USE OF ANASTROZOLE AS AN
ALTERNATIVE ADJUVANT THERAPY FOR EARLY BREAST
CANCER (EBC) USING DISCRETE CHOICE WILLINGNESS-TO-
PAY (WTP) METHODOLOGY
Wilson J1, Burridge J1, Gniel J2, Maclean A2, LeReun C1,Adams J1,
Davey P1
1M-TAG Australia Pty Ltd, Chatswood, NSW, Australia; 2AstraZeneca
Australia Pty Ltd, NSW, Australia
OBJECTIVES: Anastrozole provides a treatment alternative for
patients with EBC who cannot tolerate tamoxifen or in whom
the drug is contraindicated. This study aimed to examine the
value patients place on the ability of a treatment to decrease the
